Altimmune, Inc. · NASDAQ:ALT

Altimmune — AASLD The Liver Meeting 2026

19 slides from Altimmune's conference presentation, Nov 8, 2026

  1. Slide 1: Pemvidutide Treatment Results in Concurrent Reductions in Multiple Non-Invasive Tests

    Pemvidutide Treatment Results in Concurrent Reductions in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis: 48-Week Responder Analyses of the IMPACT Phase 2b Trial in Metabolic Dysfunction- Associated Steatohepatitis Naim Alkhouri1,2, Mazen Noureddin3,4, Shaheen Tomah5, John J. Susc

  2. Slide 2: Disclosures

    Disclosures Dr. Alkhouri’s Disclosures: Research support from 89bio, Akero Therapeutics, AstraZeneca, Boehringer Ingelheim, Corcept Therapeutics, Galectin Therapeutics, Genentech/ Roche, Gilead Sciences, Inventiva Pharma, Ionis Pharmaceuticals, Ipsen, Eli Lilly, Madrigal Pharmaceuticals, Merck, Novo

  3. Slide 3: MASH Overview

    INTRODUCTION MASH Overview Disease: MASH is a progressive liver disease characterized by hepatic fat accumulation, inflammation, and fibrosis,a often comorbid with obesity, type 2 diabetes, and cardiovascular diseaseb Prevalence: It affects an estimated ~5% (16-17 million) of the U.S. population and

  4. Slide 4: Pemvidutide is a balanced 1:1 glucagon/GLP-1 dual receptor agonist

    INTRODUCTION Pemvidutide is a balanced 1:1 glucagon/GLP-1 dual receptor agonist COOH (CH2)n EuPort Domain Allows for weekly dosing and may contribute to tolerabilitya Glucagon specificity GLP-1 specificity Provides direct liver effects, including liver fat Mediates metabolic effects such as appetite

  5. Slide 5: IMPACT Phase 2b MASH Trial Design

    INTRODUCTION IMPACT Phase 2b MASH Trial Design Placebo weekly (n=86) Screening & Randomization 1.2 mg pemvidutide weekly (n=41) N=212 patients 1.8 mg pemvidutide weekly (n=85) No dose titration KEY ELIGIBILITY KEY ENDPOINTS Week 24 Week 48 • Biopsy-confirmed Primary • Histologic MASH resolution or M

  6. Slide 6: Significant improvements in histology and individual NITs within 24 weeks

    INTRODUCTION Pemvidutide demonstrated significant improvements in histology and individual NITs of hepatic inflammation and fibrosis within 24 weeksa HISTOLOGY NON-INVASIVE TESTS MASH resolution Fibrosis improvement Responders, Placebo Pemvidutide Pemvidutide without worsening of fibrosis without wo

  7. Slide 7: Aim

    INTRODUCTION Aim To evaluate composite NIT responses after 48 weeks of pemvidutide treatment in the IMPACT Phase 2b trial using thresholds associated with MASH and/or fibrosis improvement LIVER FAT LIVER INJURY FIBROSIS ≥30-50% ≥17 IU/L ≥0.5 ≥30% reduction in LFCa reduction in ALTb reduction in ELF

  8. Slide 8: Definitions for Composite NIT Responses

    METHODS Definitions for Composite NIT Responses Responses defined by concurrent improvements across liver fat, liver injury, and/or fibrosis: MASH Fibrosis Disease Improvement Improvement Remission • ≥30% LFC • ≥0.5 ELF • ≥50% LFC reductiona reductiond reductiona • ≥17 IU/L ALT • ≥30% LSM • ≥0.5 ELF

  9. Slide 9: Demographic and baseline clinical characteristics were similar across groups

    RESULTS Demographic and baseline clinical characteristics were similar across groups Placebo Pemvidutide 1.2 mg Pemvidutide 1.8 mg Characteristic n=86 n=41 n=85 Age, years, mean (SD) 52.5 (12.2) 55.2 (13.0) 53.4 (12.4) Female sex, n (%) 48 (55.8) 25 (61.0) 50 (58.8) Body weight, kg, mean (SD) 109.7

  10. Slide 10: Composite responses for markers associated with MASH improvement were significantly higher

    RESULTS Composite responses for markers associated with MASH improvement were significantly higher with pemvidutide ▪ Composite NITs for markers MASH Improvement Composites NITs at Week 48 associated with MASH improvement: ▪ ≥30% LFC reduction ▪ ≥17 IU/L ALT reduction ▪ ≥30% LSM reduction ▪ The prop

  11. Slide 11: Composite response rates for NITs of fibrosis improvement were significantly higher

    RESULTS Composite response rates for NITs of fibrosis improvement were significantly higher with pemvidutide ▪ Composite NITs for fibrosis Fibrosis Improvement Composite NITs at Week 48 improvement: ▪ ≥0.5 ELF reduction ▪ ≥30% LSM reduction ▪ Response rates across multiple NITs of fibrosis improveme

  12. Slide 12: Significantly higher composite NIT response rates for disease remission

    RESULTS Pemvidutide achieved significantly higher composite NIT response rates for disease remission ▪ Disease remission composite Disease Remission Composite NITs at Week 48 NITs: ▪ ≥50% LFC reduction ▪ ≥0.5 ELF reduction ▪ ≥30% LSM reduction ▪ Both pemvidutide doses yielded significantly greater c

  13. Slide 13: Improvements in Primary Non-invasive Markers of Fibrosis from 24 to 48 Weeks

    RESULTS Improvements in Primary Non-invasive Markers of Fibrosis from 24 to 48 Weeks with 1.8 mg Enhanced Liver Fibrosis (ELF) Liver Stiffness Measurement (LSM) Placebo-Adjusted Placebo-Adjusted 0 0 LS Mean Change from Baseline (kPa ± 95% CI) -1 LS Mean Change from Baseline (± 95% CI) -0.25 -2 -3 -1

  14. Slide 14: Summary

    Summary ▪ Response rates were significantly higher with pemvidutide than placebo across all composite NIT endpoints ▪ 1.8 mg pemvidutide consistently achieved numerically higher response rates compared with 1.2 mg pemvidutide and placebo ▪ 48-week NIT findings align with trends in histologic MASH re

  15. Slide 15: Future Directions

    Future Directions ▪ The ongoing PERFORMA phase 3, global, randomized, placebo-controlled, double-blind, parallel-group trial evaluates pemvidutide in MASH, including: Longer-term histologic and safety outcomes ▪ biopsy and safety evaluation at 52 weeks ▪ event-driven follow-up through ~60 months Bio

  16. Slide 16: Acknowledgements

    Acknowledgements We thank the patients and their families for their participation in the IMPACT Phase 2b trial. This study was sponsored by Altimmune, Inc. Medical communications support Boston Strategic Partners, Inc., which was funded by Altimmune, Inc. Slides are the property of the authors and A

  17. Slide 17: Thank you! Questions?

    Thank you! Questions? AASLD

  18. Slide 18: Appendix

    Appendix AASLD

  19. Slide 19: IMPACT Phase 2b MASH Trial Patient Disposition

    Appendix IMPACT Phase 2b MASH Trial Patient Disposition 212 randomized Placebo (n=86) Pemvidutide 1.2 mg (n=41) Pemvidutide 1.8 mg (n=85) 20 discontinued 13 discontinued 6 discontinued 3 adverse events 1 adverse event 6 other 17 other 12 other 66 completed treatment 35 completed treatment 72 complet

Altimmune — AASLD The Liver Meeting 2026 on 6ix